Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Zogenix, Inc.    ZGNX

ZOGENIX, INC. (ZGNX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/16/2018 04/17/2018 04/18/2018 04/19/2018 04/20/2018 Date
40.25(c) 41.45(c) 40.85(c) 40.9(c) 40.8(c) Last
465 979 702 888 655 168 503 490 353 897 Volume
+0.25% +2.98% -1.45% +0.12% -0.24% Change
More quotes
Financials (USD)
Sales 2018 -
EBIT 2018 -104 M
Net income 2018 -105 M
Debt 2018 -
Yield 2018 -
Sales 2019 60,4 M
EBIT 2019 -63,5 M
Net income 2019 -59,6 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 0
Capi. / Sales2019 23,6x
Capitalization 1 427 M
More Financials
Company
Zogenix, Inc. is a pharmaceutical company, which engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders.It develops two products candidate: ZX008 and Relday.The company was founded by Stephen... 
More about the company
Surperformance© ratings of Zogenix, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on ZOGENIX, INC.
04/16ZOGENIX : to Participate in LEERINK Partners CNS Day
AQ
04/16ZOGENIX : Metropolitan Life Insurance Co. NY Has $435,000 Position in Zogenix, I..
AQ
04/11ZOGENIX : to Participate in LEERINK Partners CNS Day
AQ
03/12ZOGENIX : Provides Corporate Update and Reports Fourth Quarter and Full-Year 201..
AQ
03/06ZOGENIX : Management's Discussion and Analysis of Financial Condition and Result..
AQ
03/06ZOGENIX : reports 4Q loss
AQ
03/06ZOGENIX, INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
03/06Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 20..
GL
03/06ZOGENIX, INC. : to Host Earnings Call
AC
02/27Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Ho..
GL
More news
Sector news : Bio Medical Devices
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
04/12UK gene therapy firm Orchard plans stock offer after GSK deal
RE
04/12TAKEDA SOUNDS OUT BANKS FOR LOANS AS : sources
RE
More sector news : Bio Medical Devices
Latest Tweets
04/21Zogenix $ZGNX Receives Daily Coverage Optimism Score of 0.12  
04/20Incredible view from Pineridge! Add your photos to our gallery: https://t.co..
1
04/20$ZGNX - Stock Traders Purchase High Volume of Zogenix Put Options #ZGNX  
04/20$ZGNX - Stock Traders Purchase High Volume of Zogenix Put Options #ZGNX  
04/20Stock Traders Purchase High Volume of Zogenix Put Options $ZGNX  
More tweets
Qtime:176
News from SeekingAlpha
04/19INSTITUTIONAL TOP IDEAS SERIES : Scopia Capital 
04/13INSTITUTIONAL TOP IDEAS SERIES : DAFNA Capital Management 
04/05INSTITUTIONAL TOP IDEAS SERIES : Broadfin Capital 
03/12FILING SEASON FINDS : Thursday, March 8 
03/06Zogenix's (ZGNX) CEO Stephen Farr on Q4 2017 Results - Earnings Call Transcri.. 
Chart ZOGENIX, INC.
Duration : Period :
Zogenix, Inc. Technical Analysis Chart | ZGNX | US98978L2043 | 4-Traders
Technical analysis trends ZOGENIX, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 54,6 $
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Stephen J. Farr President, Chief Executive Officer & Director
Cam L. Garner Chairman
Michael P. Smith CFO, Secretary, Treasurer & Executive VP
Bradley S. Galer Chief Medical Officer & Executive Vice President
Roger L. Hawley Director
Sector and Competitors
1st jan.Capitalization (M$)
ZOGENIX, INC.1.87%1 427
GILEAD SCIENCES3.91%96 094
VERTEX PHARMACEUTICALS6.47%40 153
REGENERON PHARMACEUTICALS-15.99%33 844
CELLTRION, INC.--.--%31 467
IQVIA HOLDINGS INC-0.64%20 258